Depression and Epilepsy: A Review of Multiple Facets of Their Close Relation

被引：107

作者：

Kanner, Andres M. ^{[1
,2
,3
,4
,5
]}

机构：

[1] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA

[2] Rush Univ, Med Ctr, Armour Acad Ctr, Dept Psychiat, Chicago, IL 60612 USA

[3] Rush Univ, Med Ctr, Lab Electroencephalog & Video EEG Telemetry, Chicago, IL 60612 USA

[4] Rush Univ, Med Ctr, Sect Epilepsy, Chicago, IL 60612 USA

[5] Rush Univ, Med Ctr, Rush Epilepsy Ctr, Chicago, IL 60612 USA

来源：

NEUROLOGIC CLINICS | 2009年 / 27卷 / 04期

关键词：

Major depressive disorder; Hippocampal atrophy; Temporal lobe epilepsy; Frontal lobe epilepsy; Anxiety disorders; QUALITY-OF-LIFE; 5-HT1A RECEPTOR-BINDING; MAJOR DEPRESSION; ANTIEPILEPTIC DRUGS; VILOXAZINE HYDROCHLORIDE; PSYCHIATRIC-SYMPTOMS; COMORBID DEPRESSION; ANTICONVULSANT; ABNORMALITIES; IMIPRAMINE;

D O I：

10.1016/j.ncl.2009.08.002

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

100204 [神经病学];

摘要：

Depressive disorders are the most frequent psychiatric comorbidity in patients with epilepsy (PWE). Although they are typically considered a psychiatric disorder, ample data suggest that depressive disorders are a neurologic disorder with psychiatric clinical manifestations. Patients with epilepsy whose seizures originate in temporal and frontal lobes have the highest prevalence of comorbid depressive disorders. Not only are patients with epilepsy at higher risk of developing depression but also patients with depression are at higher risk of developing epilepsy. This article reviews these data, the clinical manifestations of depressive disorders in PWE, and their significant impact on the suicidal risk and quality of life.

引用

页码：865 / +

页数：17

共 95 条

[1]

Seizure incidence in psychopharmacological clinical trials: An analysis of food and drug administration (FDA) summary basis of approval reports [J].